VTVT - vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference | Benzinga
HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that Company management will be presenting at the TD Cowen 44th Annual Healthcare Conference, being held March 4-6, 2024, in Boston, MA. The presentation is scheduled for Tuesday, March 5, 2024, at 9:50 AM ET.
A live webcast of the presentation will be available via the Events section of the Company's investor relations website at https://ir.vtvtherapeutics.com/events.
Investors interested in scheduling a one-on-one meeting with vTv's management should contact their TD Cowen representative.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type ...